scholarly journals Skin Toxicities of Immune Check Point Inhibitors in Solid Tumors and Managment:Review of Literature

2021 ◽  
Vol 10 (2) ◽  
Author(s):  
Mohamed réda  Khmamouche
Keyword(s):  
Solid Tumors ◽  
Check Point ◽  
Check Point Inhibitors

scholarly journals Outcomes and toxicities in sarcopenic patients with metastatic solid tumors treated with check point inhibitors.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14166-e14166
Author(s):  
Laura Haik ◽  
Aurore Gonthier ◽  
Eric Frison ◽  
Marine Gross-Goupil ◽  
Charlotte Domblides ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Multivariate Analysis ◽  
Solid Tumors ◽  
Performance Status ◽  
Objective Response ◽  
University Hospital ◽  
Check Point ◽  
Anthropometric Parameters ◽  
Significant Difference ◽  
Check Point Inhibitors

e14166 Background: Evidence suggests that sarcopenia is a significant predictor of worst outcomes and treatment toxicities in metastatic solid tumors patients (pts). We investigated whether sarcopenia was associated with outcomes and severe toxicities (ST) in patients treated with check point inhibitors (CPI). Methods: All consecutive metastatic solid tumors patients treated with CPI from January 2013 to December 2017 in Bordeaux University Hospital (France) were retrospectively reviewed. Sarcopenia was evaluated using computed tomography (CT) obtained within 1 month before treatment initiation. Skeletal muscle mass index (SMI) were measured from axial L3 CT section. Sarcopenia was defined as SMI ≤ 52.4 cm2/m2 for males and SMI ≤ 38.5 cm2/m2 for women. Clinical characteristics included Performance Status (PS) and anthropometric parameters. ST included grade III-IV according to NCI-CTC v4.0 and any grade of toxicity leading to treatment interruption. Results: Among 261 pts included, 179 (69%) had metastatic lung cancer and 151 (58%) had previously received one line of treatment. Median age was 61 years old and there were 198 males (76%). PS status was 1 in 55% of pts. CPI treatment was: anti PD1, anti PD-L1, anti CTLA-4 and CPI combination in 192, 43, 3 and 20 pts, respectively. The prevalence of sarcopenia was 64%. At inclusion, sarcopenia was associated with poor PS (p = 0.002), anorexia (p < 0.001), lower albumin (p = 0.002) and hemoglobin (p < 0.001). Objective Response Rate (ORR) was 28% in sarcopenic pts and 26% in non-sarcopenic pts. Median progression free survival (PFS) was 6.9 and 7.6 months in sarcopenic pts and non-sarcopenic pts respectively (p = 0.5). In multivariate analysis, sarcopenia was not associated with PFS or ORR. Median overall survival (mOS) was 10.2 months in lung cancer, without significant difference between sarcopenic and non-sarcopenic patients (mOS: 9 months and 17 months respectively, p = 0.06). In general population, ST occurred in 36 (14%) pts; among which 23 (64%) presented sarcopenia. In multivariate analysis, sarcopenia was not associated with ST (OR = 1.16, p = 0.71). Conclusions: Sarcopenia was not associated with outcomes or toxicities in metastatic solid tumors patients treated with CPI in this study.

Immune Checkpoint Inhibitor (ICPI) induced Nephrotoxicity – An Insight.

JMS SKIMS ◽  
2020 ◽  
Vol 23 (3) ◽  
Author(s):  
Mohmad Hussian Mir ◽  
Tariq Ahmad Bhat ◽  
Khalid Parvez Sofi ◽  
Imtiyaz Ahmad Wani ◽  
Muzafar Maqsood Wani
Keyword(s):  
Acute Kidney Injury ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Kidney Injury ◽  
Check Point ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
New Class ◽  
Transplant Patients ◽  
Check Point Inhibitors

Immune check point inhibitors (ICPIs) are a new class of anti-neoplastic agents being increasingly used by oncologists to treat various malignancies. These drugs have been associated with varied side effects and have a nephrotoxic potential. Many cases of ICPI induced acute kidney injury are increasingly being reported. Their use in CKD patients on dialysis as well as in kidney transplant recipients is associated with various challenges. This review discusses the use of ICPIs in CKD, dialysis and renal transplant patients and their nephrotoxic potential  

scholarly journals 61P Immune check point inhibitors (ICIs) in cancer therapy: An experience from a resource poor and developing country

2020 ◽  
Vol 31 ◽  
pp. S1440
Author(s):  
M. Naseer ◽  
A. Patel ◽  
A. Anand ◽  
H. Panchal ◽  
S. Parikh ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Developing Country ◽  
Check Point ◽  
Resource Poor ◽  
Check Point Inhibitors

scholarly journals Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment

2021 ◽  
Vol 11 (5) ◽  
pp. 393
Author(s):  
Francesca De Felice ◽  
Daniela Musio ◽  
Vincenzo Tombolini
Keyword(s):  
Clinical Trials ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Therapeutic Strategies ◽  
Check Point ◽  
Clinical Tool ◽  
Cancer Management ◽  
Check Point Inhibitors

In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research.

scholarly journals Cutaneous Events Associated with Immunotherapy of Melanoma: A Review

2021 ◽  
Vol 10 (14) ◽  
pp. 3047
Author(s):  
Lorenza Burzi ◽  
Aurora Maria Alessandrini ◽  
Pietro Quaglino ◽  
Bianca Maria Piraccini ◽  
Emi Dika ◽  
...  
Keyword(s):  
Adverse Events ◽  
Checkpoint Inhibitors ◽  
Stage Iii ◽  
Check Point ◽  
Check Point Inhibitors

Immunotherapy with checkpoint inhibitors significantly improves the outcome for stage III and IV melanoma. Cutaneous adverse events during treatment are often reported. We herein aim to review the principal pigmentation changes induced by immune check-point inhibitors: the appearance of vitiligo, the Sutton phenomenon, melanosis and hair and nail toxicities.

scholarly journals Immune Check-Point Inhibitors in Breast Cancer: Current Evidence and Future Directions

2021 ◽  
Vol 8 (3) ◽  
Author(s):  
Mosteiro M ◽  
◽  
Cejuela M ◽  
Pernas S ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Triple Negative ◽  
New Combination ◽  
Current Evidence ◽  
Check Point ◽  
Future Directions ◽  
Combination Strategies ◽  
Check Point Inhibitors

Check-point inhibitors have erupted as a treatment option for numerous kinds of neoplasms. Although there have been some achievements, the evidence supporting their use in breast cancer is scarce. Combinations with chemotherapy seem to provide better outcomes, and triple negative is the subtype most likely to benefit from them. New combination strategies are undergoing research to improve these results. Other approaches to determining biomarkers that identify which populations clearly benefit from these therapies are needed. Here, we review the clinical data of the role of immune check-point inhibitors in early and advanced breast cancer and present emerging strategies.

Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

2020 ◽  
pp. 107815522096567
Author(s):  
Deniz Can Guven ◽  
Saadettin Kilickap ◽  
Hasan Cagri Yildirim ◽  
Furkan Ceylan ◽  
Onur Bas ◽  
...  
Keyword(s):  
Case Report ◽  
Ewing Sarcoma ◽  
Treatment Options ◽  
Distinct Type ◽  
Salvage Treatment ◽  
Check Point ◽  
Check Point Inhibitors ◽  
Poorly Differentiated ◽  
Aggressive Tumor ◽  
Cessation Of Treatment

Introduction Although, immune check-point inhibitors changed the course of many cancers, the outcomes in sarcomas were rather disappointing with less than 10% response rates. Ewing sarcoma is a poorly differentiated and aggressive tumor mostly seen in the children and adolescents. It’s a distinct type of sarcoma with prominent chemosensitivity in the early stages. However, the relapsing disease has a poor prognosis with limited treatment options. Case report Herein, we represent a case of relapsed Ewing sarcoma treated with multiple lines of chemotherapy. Management & outcome: The patient had a very good response to salvage treatment with a combination of paclitaxel and nivolumab which lasted for twelve months after the cessation of treatment. Discussion We think that chemotherapy plus immunotherapy can be an option for Ewing sarcoma patients treated with multiple lines of chemotherapy.

Durvalumab-associated vasculitis presenting as ‘the blue toe syndrome’

2020 ◽  
Vol 13 (11) ◽  
pp. e235886
Author(s):  
Shivangi Gupta ◽  
Dan Xu ◽  
Jane Hadfield ◽  
David Prentice
Keyword(s):  
Clinical Success ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Small Cell ◽  
Check Point ◽  
Small Cell Lung ◽  
Livedo Racemosa ◽  
Free Survival ◽  
Check Point Inhibitors ◽  
Blue Toe Syndrome

Durvalumab is a selective, high-affinity human immunoglobulin monoclonal antibody in a class called check point inhibitors, that blocks PD-L1 on tumour cells. Despite clinical success in increasing progression-free survival rates in patients with stage III non-small-cell lung cancer, durvalumab has been associated with immune-related side effects such as pneumonitis and colitis. We present a case of an 84-year-old woman with acral vasculitis presenting as blue toe syndrome, associated with prolonged use of durvalumab. After 1 year of fortnightly durvalumab therapy postchemoradiation therapy, the patient came in with a left blue big toe, and later developed bilateral livedo racemosa. The diagnosis of durvalumab-associated vasculitis was made and treatment with prednisolone was started with clinical improvement.

Sign in / Sign up

Export Citation Format

Share Document